106 related articles for article (PubMed ID: 11522620)
1. Loss of annexin II heavy and light chains in prostate cancer and its precursors.
Chetcuti A; Margan SH; Russell P; Mann S; Millar DS; Clark SJ; Rogers J; Handelsman DJ; Dong Q
Cancer Res; 2001 Sep; 61(17):6331-4. PubMed ID: 11522620
[TBL] [Abstract][Full Text] [Related]
2. INSL3 in the benign hyperplastic and neoplastic human prostate gland.
Klonisch T; Müller-Huesmann H; Riedel M; Kehlen A; Bialek J; Radestock Y; Holzhausen HJ; Steger K; Ludwig M; Weidner W; Hoang-Vu C; Hombach-Klonisch S
Int J Oncol; 2005 Aug; 27(2):307-15. PubMed ID: 16010410
[TBL] [Abstract][Full Text] [Related]
3. A quantitative promoter methylation profile of prostate cancer.
Jerónimo C; Henrique R; Hoque MO; Mambo E; Ribeiro FR; Varzim G; Oliveira J; Teixeira MR; Lopes C; Sidransky D
Clin Cancer Res; 2004 Dec; 10(24):8472-8. PubMed ID: 15623627
[TBL] [Abstract][Full Text] [Related]
4. Dysregulation of annexin I protein expression in high-grade prostatic intraepithelial neoplasia and prostate cancer.
Kang JS; Calvo BF; Maygarden SJ; Caskey LS; Mohler JL; Ornstein DK
Clin Cancer Res; 2002 Jan; 8(1):117-23. PubMed ID: 11801547
[TBL] [Abstract][Full Text] [Related]
5. Expression of biomarkers modulating prostate cancer angiogenesis: differential expression of annexin II in prostate carcinomas from India and USA.
Banerjee AG; Liu J; Yuan Y; Gopalakrishnan VK; Johansson SL; Dinda AK; Gupta NP; Trevino L; Vishwanatha JK
Mol Cancer; 2003 Oct; 2():34. PubMed ID: 14613585
[TBL] [Abstract][Full Text] [Related]
6. Differential expression of galectins in normal, benign and malignant prostate epithelial cells: silencing of galectin-3 expression in prostate cancer by its promoter methylation.
Ahmed H; Banerjee PP; Vasta GR
Biochem Biophys Res Commun; 2007 Jun; 358(1):241-6. PubMed ID: 17481580
[TBL] [Abstract][Full Text] [Related]
7. Annexin II expression is reduced or lost in prostate cancer cells and its re-expression inhibits prostate cancer cell migration.
Liu JW; Shen JJ; Tanzillo-Swarts A; Bhatia B; Maldonado CM; Person MD; Lau SS; Tang DG
Oncogene; 2003 Mar; 22(10):1475-85. PubMed ID: 12629510
[TBL] [Abstract][Full Text] [Related]
8. Expression of ezrin in prostatic intraepithelial neoplasia.
Pang ST; Fang X; Valdman A; Norstedt G; Pousette A; Egevad L; Ekman P
Urology; 2004 Mar; 63(3):609-12. PubMed ID: 15028477
[TBL] [Abstract][Full Text] [Related]
9. Signal transducer and activator of transcription-6 (STAT6) is a constitutively expressed survival factor in human prostate cancer.
Das S; Roth CP; Wasson LM; Vishwanatha JK
Prostate; 2007 Oct; 67(14):1550-64. PubMed ID: 17705178
[TBL] [Abstract][Full Text] [Related]
10. Deletion, methylation, and expression of the NKX3.1 suppressor gene in primary human prostate cancer.
Asatiani E; Huang WX; Wang A; Rodriguez Ortner E; Cavalli LR; Haddad BR; Gelmann EP
Cancer Res; 2005 Feb; 65(4):1164-73. PubMed ID: 15734999
[TBL] [Abstract][Full Text] [Related]
11. Appearance of angiotensin II expression in non-basal epithelial cells is an early feature of malignant change in human prostate.
Louis SN; Wang L; Chow L; Rezmann LA; Imamura K; MacGregor DP; Casely D; Catt KJ; Frauman AG; Louis WJ
Cancer Detect Prev; 2007; 31(5):391-5. PubMed ID: 18031950
[TBL] [Abstract][Full Text] [Related]
12. Up-regulation of cathepsin X in prostate cancer and prostatic intraepithelial neoplasia.
Nägler DK; Krüger S; Kellner A; Ziomek E; Menard R; Buhtz P; Krams M; Roessner A; Kellner U
Prostate; 2004 Jul; 60(2):109-19. PubMed ID: 15162377
[TBL] [Abstract][Full Text] [Related]
13. The expression of thrombospondin-1 in benign prostatic hyperplasia and prostatic intraepithelial neoplasia is decreased in prostate cancer.
Vallbo C; Wang W; Damber JE
BJU Int; 2004 Jun; 93(9):1339-43. PubMed ID: 15180634
[TBL] [Abstract][Full Text] [Related]
14. HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer.
Montironi R; Mazzucchelli R; Barbisan F; Stramazzotti D; Santinelli A; Scarpelli M; Lòpez Beltran A
Hum Pathol; 2006 Sep; 37(9):1137-44. PubMed ID: 16938518
[TBL] [Abstract][Full Text] [Related]
15. Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with gleason score and chromosome 8p deletion.
Bethel CR; Faith D; Li X; Guan B; Hicks JL; Lan F; Jenkins RB; Bieberich CJ; De Marzo AM
Cancer Res; 2006 Nov; 66(22):10683-90. PubMed ID: 17108105
[TBL] [Abstract][Full Text] [Related]
16. Functional Loss of the gamma-catenin gene through epigenetic and genetic pathways in human prostate cancer.
Shiina H; Breault JE; Basset WW; Enokida H; Urakami S; Li LC; Okino ST; Deguchi M; Kaneuchi M; Terashima M; Yoneda T; Shigeno K; Carroll PR; Igawa M; Dahiya R
Cancer Res; 2005 Mar; 65(6):2130-8. PubMed ID: 15781623
[TBL] [Abstract][Full Text] [Related]
17. Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia.
Kang GH; Lee S; Lee HJ; Hwang KS
J Pathol; 2004 Feb; 202(2):233-40. PubMed ID: 14743506
[TBL] [Abstract][Full Text] [Related]
18. Promoter hyper-methylation of calcium binding proteins S100A6 and S100A2 in human prostate cancer.
Rehman I; Cross SS; Catto JW; Leiblich A; Mukherjee A; Azzouzi AR; Leung HY; Hamdy FC
Prostate; 2005 Dec; 65(4):322-30. PubMed ID: 16015609
[TBL] [Abstract][Full Text] [Related]
19. Insulin-like growth factor (IGF)-I, IGF-II and IGF type I receptor (IGFR-I) expression in prostatic cancer.
Cardillo MR; Monti S; Di Silverio F; Gentile V; Sciarra F; Toscano V
Anticancer Res; 2003; 23(5A):3825-35. PubMed ID: 14666684
[TBL] [Abstract][Full Text] [Related]
20. Functional epigenomics identifies genes frequently silenced in prostate cancer.
Lodygin D; Epanchintsev A; Menssen A; Diebold J; Hermeking H
Cancer Res; 2005 May; 65(10):4218-27. PubMed ID: 15899813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
